HDAC6's role in immune cells during sepsis
HDAC6 regulation of myeloid cell responses in sepsis
['FUNDING_R01'] · UNIVERSITY OF KENTUCKY · NIH-11163439
This work looks at whether blocking a protein called HDAC6 can help immune cells work better and improve survival in sepsis.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF KENTUCKY (nih funded) |
| Locations | 1 site (LEXINGTON, UNITED STATES) |
| Trial ID | NIH-11163439 on ClinicalTrials.gov |
What this research studies
Researchers will use mouse models and isolated immune cells to study how the protein HDAC6 changes myeloid (innate immune) cell behavior during sepsis. They will remove or inhibit HDAC6 specifically in myeloid cells and then expose the animals or cells to septic conditions to see how immune responses change. The team will examine cell signaling, metabolism, epigenetic marks, and cell survival to understand why HDAC6 affects immune function. If the lab results are promising, they could inform development of new treatments that target HDAC6 for people with sepsis.
Who could benefit from this research
Good fit: People who have sepsis or are at high risk of developing sepsis would be the eventual candidates for therapies based on this work.
Not a fit: People without sepsis or whose illness is driven primarily by non-immune mechanisms are unlikely to benefit directly from this specific line of research.
Why it matters
Potential benefit: If successful, this could point to new therapies that protect immune cells and improve survival in sepsis.
How similar studies have performed: Preclinical mouse studies have shown promising effects of HDAC6 deletion or inhibition on immune responses and survival, but this approach has not yet been tested in people.
Where this research is happening
LEXINGTON, UNITED STATES
- UNIVERSITY OF KENTUCKY — LEXINGTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: FU, JIAN — UNIVERSITY OF KENTUCKY
- Study coordinator: FU, JIAN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.